Pulmatrix Inc (PULM): "We suspect Mylan may not offer an actio...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	52
Boards Moderated	0
Alias Born	03/23/2016

iambillytalent

Re: None

Wednesday, 03/29/2017 11:44:37 PM

Wednesday, March 29, 2017 11:44:37 PM

"We suspect Mylan may not offer an actionable timeline on its May earnings call, but the prudent decision would be to remove the product from the 2017 guidance," Leerink analyst Jason Gerberry wrote Wednesday.

Quote was taken from https://www.thestreet.com/story/14064661/2/fda-rejection-of-mylan-generic-adds-to-its-woes.html

If this is truly taken off 2017's agenda, then it sure is possible that they'll go ahead and purchase Pulmatrix. The question then would be...when?

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent PULM News

Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:06:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:00:24 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 02:20:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:05:40 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 01:20:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 01:05:29 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 08:05:12 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 01:05:21 PM